Sysmex Siemens Agreement

Sysmex Siemens Agreement

December 2020 – Siemens Healthineers has announced a master cooperation agreement with Novartis Pharma for the development, development and commercialization of diagnostic tests for therapeutic products throughout Novartis` therapeutic pipeline. The first program will focus on the development of a Neurofilament Light Chain Immunoassays serum for patients with multiple sclerosis and other neurological diseases. SysmexNoriko OkadaPhone: `81-(0) 78-265-0508; E-mail: info@sysmex.co.jp Sysmex Corporation is a global leader in clinical laboratory systems and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Sysmex has been looking after clients for more than 40 years and focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people around the world. The company is also exploring new possibilities in the field of life science. Research and development efforts focus on the development of high-quality, innovative, original and individually beneficial health testing and diagnostic technologies. Sysmex is also trying to use its state-of-the-art technologies to analyze cells, genes and proteins. Headquartered in Kobe, Japan, the company has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 7,000 people worldwide. Sysmex Corporation is listed at the top level of the Tokyo Stock Exchange. For more information about Sysmex Corporation and its subsidiaries, see www.sysmex.co.jp/en/. To learn more about Sysmex urine testing products, visit www.sysmex.com/UA. NEW YORK – Sysmex America signed an exclusive agreement with Siemens Healthineers on Monday to distribute and service the company`s automated urine analyzer in North American hospitals and reference laboratories. Sysmex Corporation (headquartered: Kobe, Japan; Chairman: Hisashi Ietsugu) and Siemens Healthcare Laboratory Diagnostics (HQ: NY, USA); Chair: Franz Walt) today announced an extension of their long-standing partnership until at least 2020.

The renewal of the contract adds at least two additional years to the global contract for supply, distribution and service for Hemostasis products. The partnership allows laboratory customers around the world to continue to benefit from the largest portfolio of hemostasis and reagent systems. The companies, which began their collaboration more than 20 years ago, have also expressed their readiness to continue joint development of Hemostasis products in order to streamline and optimize testing in laboratories around the world. The extension of the relationship was celebrated on 12 April 2016 at Siemens AG`s headquarters in Munich. LINCOLNSHIRE, fig.


Comments are closed.